Nathaniel J Washburn from Littleton, MA, age 47

Wikipedia

WashburnLangfordDoane Expediti the free ...

view source

The Washburn Expedition of 1870, explored the region of northwestern Wyoming that a couple years later became Yellowstone National Park. Led by Henry Washburn, Nathaniel P. Langford ...

Us Patents

Ms Methods To Evaluate Glycans
view source
US Patent:

8043863, Oct 25, 2011
Filed:

Apr 15, 2008
Appl. No.:

12/595894
Inventors:

Carlos J. Bosques - Arlington MA, US
Nathaniel J. Washburn - Belmont MA, US
Xiangping Zhu - North Grafton MA, US
Ian Christopher Parsons - Belmont MA, US
Assignee:

Momenta Pharmaceuticals, Inc. - Cambridge MA
International Classification:

G01N 24/00
US Classification:

436174, 436173, 702 19, 702 22, 702 23, 702 32
Abstract:

The present disclosure provides, among other things, methods for the identification of sulfated glycans in a mixture of glycans.

Gal Alpha 1-3Gal-Containing N-Glycans In Glycoprotein Products Derived From Cho Cells
view source
US Patent:

20110045496, Feb 24, 2011
Filed:

Jan 22, 2009
Appl. No.:

12/529109
Inventors:

Carlos Bosques - Arlington MA, US
Jennifer Murphy - Marshfield MA, US
Hetal Sarvaiya - Quincy MA, US
Nathaniel Washburn - Belmont MA, US
Cuihua Liu - Belmont MA, US
International Classification:

G01N 33/53
C12Q 1/02
US Classification:

435 721, 435 29
Abstract:

The present invention provides methods of evaluating CHO cells.

Antennary Fucosylation In Glycoproteins From Cho Cells
view source
US Patent:

20110136682, Jun 9, 2011
Filed:

Dec 3, 2010
Appl. No.:

12/959811
Inventors:

Carlos J. Bosques - Arlington MA, US
Cuihua Liu - Belmont MA, US
Jennifer Murphy - Marshfield MA, US
Nathaniel J. Washburn - Littleton MA, US
Assignee:

MOMENTA PHARMACEUTICALS, INC. - Cambridge MA
International Classification:

C40B 30/00
C12Q 1/02
C12P 21/00
C07K 14/00
C12N 5/071
C12Q 1/34
C12Q 1/68
C12Q 1/48
G01N 27/447
H01J 49/00
G01J 1/58
G01J 1/42
G01N 21/00
G01R 33/44
US Classification:

506 7, 435 29, 435 691, 530395, 435358, 435 18, 435 61, 435 15, 204450, 250281, 2504581, 250372, 356432, 324309
Abstract:

The present invention provides methods of evaluating CHO cells and producing recombinant glycoproteins.

N-Acetylhexosamine-Containing N-Glycans In Glycoprotein Products
view source
US Patent:

20120295273, Nov 22, 2012
Filed:

Mar 12, 2012
Appl. No.:

13/417895
Inventors:

Nathaniel J. Washburn - Littleton MA, US
Enrique Arevalo - Dorchester MA, US
Kevin Millea - Saugus MA, US
Carlos J. Bosques - Arlington MA, US
Jay Duffner - Shirley MA, US
Brian E. Collins - Arlington MA, US
International Classification:

G01N 33/68
G01N 27/62
G01N 21/25
G01N 30/02
G01N 24/08
G01N 33/53
G01N 21/64
G01N 27/26
US Classification:

435 71, 435 18, 436 87, 435 29
Abstract:

The present invention provides methods of evaluating a glycoprotein preparation for the absence, presence or amount of an N-acetylhexosamine glycan, e.g., an N-acetylglucosamine glycan.

Gal Alpha 1-3Gal-Containing N-Glycans In Glycoprotein Products Derived From Cho Cells
view source
US Patent:

20140045212, Feb 13, 2014
Filed:

Oct 17, 2013
Appl. No.:

14/056674
Inventors:

Jennifer Murphy - Marshfield MA, US
Hetal Sarvaiya - Quincy MA, US
Nathaniel Washburn - Belmont MA, US
Cuihua Liu - Belmont MA, US
Assignee:

Momenta Pharmaceuticals, Inc. - Cambridge MA
International Classification:

C12P 21/00
US Classification:

435 691
Abstract:

The present invention provides methods of evaluating CHO cells.

Fcrn Antibodies And Methods Of Use Thereof
view source
US Patent:

20230049725, Feb 16, 2023
Filed:

Apr 28, 2022
Appl. No.:

17/661070
Inventors:

- Titusville NJ, US
Sucharita Roy - Acton MA, US
Nathaniel Washburn - Littleton MA, US
Marilyn Kehry - San Diego CA, US
David J. King - Encinitas CA, US
Anthony Manning - Cambridge MA, US
James Meador, III - Framingham MA, US
Jan Hillson - , US
International Classification:

C07K 16/28
A61P 37/02
Abstract:

The present application features antibodies that bind to human neonatal Fc receptor (FcRn). These anti-FcRn antibodies are useful, e.g., to promote clearance of autoantibodies in a subject, to suppress antigen presentation in a subject, to block an immune response, e.g., block an immune complex-based activation of the immune response in a subject, and to treat immunological diseases (e.g., autoimmune diseases) in a subject. These anti-FcRn antibodies are also useful, e.g., to decrease pathogenic antibody transport across the placenta of a pregnant subject, to increase pathogenic antibody catabolism in a pregnant subject, and to treat an antibody-mediated enhancement of viral disease in a fetus or a neonate.

Fcrn Antibody Compositions
view source
US Patent:

20210340251, Nov 4, 2021
Filed:

Jul 19, 2019
Appl. No.:

17/260334
Inventors:

- Cambridge MA, US
Michael SHIFRIN - Cambridge MA, US
Nathaniel J. WASHBURN - Cambridge MA, US
Aneta LIWOSZ - Cambridge MA, US
Nasir KHAN - Cambridge MA, US
International Classification:

C07K 16/28
G01N 30/74
G01N 30/72
G01N 30/86
H01J 49/16
Abstract:

This disclosure pertains to compositions comprising an anti-FcRn antibody, M281. The compositions include the full, intact antibody and size variants thereof that not include two antibody heavy chains and to antibody light chains. Thus, a M281 pharmaceutical composition can include: an antibody comprising a heavy chain comprising the amino acid sequence of SEQ ID NO:2 and a light chain comprising the amino acid sequence of SEQ ID NO:1, wherein the composition comprises a major protein component having a molecular weight of 140,00-145,000 Da and a minor protein component of molecular weight 118,000-120,000 Da.

Sialylated Glycoproteins
view source
US Patent:

20210277438, Sep 9, 2021
Filed:

Nov 20, 2020
Appl. No.:

17/100428
Inventors:

- Cambridge MA, US
Robin Meccariello - Brighton MA, US
Jonathan C. Lansing - Reading MA, US
Daniel Ortiz - Stoneham MA, US
Hetal Sarvaiya - Foster City CA, US
Nathaniel J. Washburn - Littleton MA, US
International Classification:

C12P 21/00
C12N 9/10
C07K 16/00
C12Q 1/48
Abstract:

Glycoproteins having particular sialylation patterns, and methods of making and using such glycoproteins, are described.